The participation rate of patients in pharmacogenomic trials has been the focus of recent study. The research has concluded that there are a number of factors at the patient, physician, institution and community level that serve as incentives or hindrances for clinical trial participation, including beliefs and attitudes, awareness, opportunities and resources.
